Table 2 Cost-effectiveness of DTx for hypertension
From: Cost-effectiveness of digital therapeutics for essential hypertension
Outcome | DTx + TAU | TAU-only | Changes |
|---|---|---|---|
Lifetime horizon | |||
Costs | ¥3,924,075 ($34,122) | ¥3,813,358 ($33,160) | ¥110,717 ($962) |
QALYs | 18.778 | 18.686 | 0.092 |
ICER | ¥1,199,880 ($10,434)/QALYa | ||
40-year time horizon | |||
Costs | ¥3,705,428 | ¥3,591,385 | ¥114,043 |
QALYs | 18.483 | 18.395 | 0.089 |
ICER | ¥1,284,159 ($11,167)/QALY | ||
30-year time horizon | |||
Costs | ¥2,996,162 | ¥2,869,894 | ¥126,268 |
QALYs | 17.195 | 17.124 | 0.071 |
ICER | ¥1,788,344 ($15,551)/QALY | ||
20-year time horizon | |||
Costs | ¥1,820,066 | ¥1,664,483 | ¥155,583 |
QALYs | 13.939 | 13.903 | 0.037 |
ICER | ¥4,235,677 ($36,832)/QALY | ||
